MedWatch

Gubra enters million-dollar agreement with big pharma

The Danish biotech company Gubra has announced a collaboration with a major German drug group for the development of novel peptide compounds. The deal has a potential value of EUR 250 million or approximately DKK 2 billion.

Foto: Colourbox

Although Gubra only recently concluded an important collaboration with Sanofi, the Danish biotech company has already found a new partner.

Gubra and the German drug giant Boehringer Ingelheim announced a collaboration and license agreement for the development of novel peptide compounds to treat obesity late last week.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Agilent Technologies opjusterer

Laboratorieleverandøren Agilent Technologies har haft et stærkt forskudt tredje kvartal, og opjusterer forventningerne for helåret.

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier